Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Ns3 4a protease"'
Autor:
Nese Kurt Yilmaz, Desaboini Nageswara Rao, Hasahn L. Conway, Mohsan Saeed, Alicia Newton, Adam K. Hedger, Jacqueto Zephyr, Ashley N. Matthew, Akbar Ali, Mina Henes, Elise T Chan, Wei Huang, Christos J. Petropoulos, Celia A. Schiffer
Publikováno v:
J Med Chem
The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use-grazoprevir, glecaprevir, and voxilaprevir-are quinoxaline-based P2-P4 macrocycles and thus exhibit similar resistance profiles. Using our quinoxaline-based P1-P3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5522535181ab0aabd2f1c0ce6ac851ee
https://doi.org/10.1021/acs.jmedchem.1c00554
https://doi.org/10.1021/acs.jmedchem.1c00554
Autor:
Nicholas A. Meanwell, Ravi Kumar Trivedi, Tatyana Zvyaga, Richard Rampulla, Sarkunam Kandhasamy, Debarati Mazumder Tagore, Sureshbabu Vishwakrishnan, Arvind Mathur, Sunitha Puttaswamy, Abhijith Rao, Hua Fang, Sankar Sivaprasad, Susan Jenkins, Eric Mull, Kathy Mosure, Kaushik Ghosh, Barbara Zheng, Subba Reddy, Fiona McPhee, Chaoqun Chen, Bowsher Michael S, James Loy, Ying-Kai Wang, Amit Kumar, Ramkumar Rajamani, Kishore Rendunchintala, Paul Michael Scola, Gillis Eric P, Salil D. Desai, Li-Qiang Sun, Rushith Kumar Anumula, Nagalakshmi Pulicharla, Sheldon Hiebert, Venkata Rao Baratam, Paul Falk, Sarmistha Sinha, Stanley D'andrea
Publikováno v:
Journal of Medicinal Chemistry. 63:14740-14760
The discovery of a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based on a P1–P3 macrocyclic tripeptide motif is described. The all-carbon tether linking the P1–P3 subsites of 21...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9fae1c3f9b157cd2f44f9613c2d3455
https://doi.org/10.1021/acs.jmedchem.0c01296
https://doi.org/10.1021/acs.jmedchem.0c01296
Autor:
Daniel D. Caspi, Kenneth M. Engstrom, Seble H. Wagaw, Nandkishor K. Nere, Dean S. Clyne, Clifford Mitchell, Timothy A. Grieme, Ahmad Y. Sheikh, Jianzhang Mei, Moiz Diwan, Hongqiang Zhang, Robert W. Miller, Russell D. Cink, Matthew M. Ravn, José G. Napolitano
Publikováno v:
Tetrahedron. 75:4271-4286
ABT-450 (8), a potent hepatitis C (HCV) NS3/4A protease inhibitor, was approved as part of AbbVie's first generation HCV treatment for the United States in December 2014. A series of process optimizations were developed over six years to support the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3474018a8bbe12903d6fc0b66dec7400
https://doi.org/10.1016/j.tet.2019.05.064
https://doi.org/10.1016/j.tet.2019.05.064
Hepatitis C virus (HCV) infection is a global threat to human health with an estimated 1.75 million new cases in 2015. Our previous studies showed that the ethyl acetate extraction of Daphne papyracea exhibited an inhibitory effect towards the HCV NS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60c201cb638bc0d92702504d44f3f376
Autor:
Sanja Glisic, Milan Sencanski
Publikováno v:
Frontiers in Clinical Drug Research-Anti Infectives
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Clinical Drug Research: Anti-Infectives
The hepatitis C virus (HCV) infection is a major and rising global health problem, affecting more than 71 million people worldwide. HCV is connected with several hepatic and extrahepatic disorders, containing several malignancies. Improved HCV detect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09cc77bb27850a8d39b3e96bbd19d124
https://vinar.vin.bg.ac.rs/handle/123456789/9689
https://vinar.vin.bg.ac.rs/handle/123456789/9689
Publikováno v:
Virology. 557:101-102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3dccfe28cb6817b439c773fe3eaf62d
https://doi.org/10.1016/j.virol.2021.01.013
https://doi.org/10.1016/j.virol.2021.01.013
Publikováno v:
Organic letters. 20(22)
An efficient synthesis of grazoprevir is reported. Starting from four readily available building blocks, grazoprevir is prepared in 51% overall yield and >99.9% purity for pharmaceutical use.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44d8795dd104c806fd8363738130dcc
https://pubmed.ncbi.nlm.nih.gov/30388018
https://pubmed.ncbi.nlm.nih.gov/30388018
Publikováno v:
European Journal of Inflammation, Vol 16 (2018)
This study aims to investigate the relationship between hepatitis C virus (HCV) NS3/4A and endogenous interferon regulatory factor-3 (IRF-3). The localization of endogenous IRF-3 protein before and after virus infection was analyzed by immunofluoresc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe1e79e9050ae415fb0fa2eb15dcccf5
https://doaj.org/article/d018cc48c3014bf884a0b2940ac6ba42
https://doaj.org/article/d018cc48c3014bf884a0b2940ac6ba42
Autor:
Guofeng Cheng, Diana M. Brainard, Eric Lawitz, Jenny C. Yang, Hongmei Mo, Michael D. Miller, James G Taylor, Hadas Dvory-Sobol, Luisa M. Stamm
Publikováno v:
Antiviral therapy. 23(4)
Background Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1–6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391f13ee27cc6b0a1ec972f4ecf977bc
https://pubmed.ncbi.nlm.nih.gov/29063860
https://pubmed.ncbi.nlm.nih.gov/29063860
Publikováno v:
The protein journal. 36(5)
Over the last 2 decades, covalent inhibitors have gained much popularity and is living up to its reputation as a powerful tool in drug discovery. Covalent inhibitors possess many significant advantages including increased biochemical efficiency, prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ebb702475cd91be40d33892210068b
https://pubmed.ncbi.nlm.nih.gov/28815420
https://pubmed.ncbi.nlm.nih.gov/28815420